CSC's DVC Enters Clinical Trial for Plague Vaccine Candidate
10 1월 2005 - 11:01PM
PR Newswire (US)
CSC's DVC Enters Clinical Trial for Plague Vaccine Candidate EL
SEGUNDO, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Computer
Sciences Corporation (NYSE:CSC) today announced that DVC LLC, a CSC
company, has entered into a phase 1 clinical trial for its
recombinant plague vaccine candidate. The trial will evaluate the
safety, tolerability and immunogenicity of the vaccine candidate in
healthy volunteers between the ages of 18 and 40. Testing is
underway and will continue into 2005 at the University of Kentucky
Chandler Medical Center in Lexington, Ky. Contract research
services for the single center open-label study will be provided by
the Covalent Group Inc. (NASDAQ:CVGR), headquartered in Wayne,
Penn. The plague vaccine candidate is designed to provide
protection against the plague bacterium Yersinia pestis, and was
originally identified and developed by scientists working at the
U.S. Army Medical Research Institute of Infectious Diseases
(USAMRIID). Their work involved the identification of suitable
protein antigens and the development of the processes used to
assess the performance of the vaccine. Further development and
manufacture of the vaccine candidate has been achieved by ID
Biomedical Corporation (NASDAQ:IDBE), headquartered in Vancouver,
British Columbia, under the DVC prime systems contract for the
Department of Defense Joint Vaccine Acquisition Program (JVAP).
JVAP's mission is to develop, produce and stockpile FDA-licensed
vaccine products to help protect the warfighter against biological
warfare agents. JVAP consolidates the Department of Defense's
efforts for the advanced development, testing, FDA licensing,
production and storage of biological defense vaccines. USAMRIID,
located at Fort Detrick, Md., is the lead medical research
laboratory for the U.S. Biological Defense Research Program, and
plays a key role in national defense and in infectious disease
research. The Institute's mission is to conduct basic and applied
research on biological threats resulting in medical solutions (such
as vaccines, drugs and diagnostics) to protect the warfighter.
USAMRIID is a subordinate laboratory of the U.S. Army Medical
Research and Materiel Command. DVC is a biopharmaceutical company
dedicated to the development and licensure of safe and efficacious
biodefense vaccines and therapeutics. DVC is part of CSC's
Enforcement, Security and Intelligence organization, which CSC
created in 2002 to support programs enhancing U.S. security. The
safety and efficacy of this product in humans has not been
established. This product is currently under clinical investigation
and has not been licensed by the FDA. About CSC Founded in 1959,
Computer Sciences Corporation is a leading global information
technology (IT) services company. CSC's mission is to provide
customers in industry and government with solutions crafted to meet
their specific challenges and enable them to profit from the
advanced use of technology. With approximately 91,000 employees,
CSC provides innovative solutions for customers around the world by
applying leading technologies and CSC's own advanced capabilities.
These include systems design and integration; IT and business
process outsourcing; applications software development; Web and
application hosting; and management consulting. Headquartered in El
Segundo, Calif., CSC reported revenue of $15.3 billion for the 12
months ended Oct. 1, 2004. For more information, visit the
company's Web site at http://www.csc.com/. DATASOURCE: Computer
Sciences Corporation CONTACT: April Finnen, Public Relations of DVC
LLC, +1-301-607-5004, ; or Rich Venn, Media Relations, Corporate of
Computer Sciences Corporation, +1-310-615-3926, Web site:
http://www.csc.com/
Copyright
ID Biomedical (NASDAQ:IDBE)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
ID Biomedical (NASDAQ:IDBE)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
ID Biomedical - Common Shares (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More ID Biomedical (MM) News Articles